A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections

The arthritogenic alphavirus, chikungunya virus (CHIKV), is now present in almost 100 countries worldwide. Further spread is very likely, which raises public health concerns. CHIKV infections cause fever and arthralgia, which can be debilitating and last for years. Here, we describe a CHIKV vaccine...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Christin Schmidt, Erik Haefner, Julia Gerbeth, Tim Beissert, Ugur Sahin, Mario Perkovic, Barbara S. Schnierle
Формат: Artigo
Язык:Inglês
Опубликовано: Elsevier 2022-06-01
Серии:Molecular Therapy: Nucleic Acids
Предметы:
MT: Delivery Strategies
chikungunya virus
RNA vaccine
protection
replicon
taRNA
Online-ссылка:http://www.sciencedirect.com/science/article/pii/S2162253122001135
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы